The glutaminase inhibitor telaglenastat hydrochloride (CB-839 HCl) is under study in the BeGIN Study (phase II NCT03872427, Table 3), enrolling patients with tumors harboring defined genetic mutations such as NF1 mutation for MPNST [101]. This evidence concerns the gene NF1 and malignant peripheral nerve sheath tumor.